| 17.77 0.21 (1.2%) | 01-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 20.79 |
1-year : | 24.28 |
| Resists | First : | 17.79 |
Second : | 20.79 |
| Pivot price | 16.88 |
|||
| Supports | First : | 16.62 |
Second : | 15.89 |
| MAs | MA(5) : | 17.36 |
MA(20) : | 16.74 |
| MA(100) : | 17.82  |
MA(250) : | 17.52 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 97.2 |
D(3) : | 96.2 |
| RSI | RSI(14): 68.4 |
|||
| 52-week | High : | 19.79 | Low : | 15.76 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ HQH ] has closed above the upper band by 4.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 48.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.81 - 17.86 | 17.86 - 17.92 |
| Low: | 17.39 - 17.45 | 17.45 - 17.53 |
| Close: | 17.66 - 17.75 | 17.75 - 17.86 |
Tekla Healthcare Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. It was previously known as H&Q Healthcare Investors. Tekla Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
Wed, 15 Jan 2025
When (HQH) Moves Investors should Listen - Stock Traders Daily
Tue, 14 Nov 2023
HQH: New Name But Same Risky Bets On Biotech - Seeking Alpha
Mon, 25 Sep 2023
Insider Buying: President Daniel Omstead Acquires 9,500 Shares of Tekla Healthcare Investors (HQH) - Yahoo Finance
Wed, 06 Sep 2023
THQ: Still The Best Of The Tekla Suite (NYSE:THQ) - Seeking Alpha
Tue, 20 Jun 2023
abrdn to Acquire US Specialist Healthcare Closed-End Funds with $3 Billion AUM - AccessWire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 52 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 161 (K) |
| Shares Short P.Month | 67 (K) |
| EPS | 3.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.9 |
| Profit Margin | 730.9 % |
| Operating Margin | -0.6 % |
| Return on Assets (ttm) | -0.1 % |
| Return on Equity (ttm) | 7.3 % |
| Qtrly Rev. Growth | -5.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 14.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 5.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.89 |
| Price to Sales | 92.91 |
| Price to Cash Flow | 0 |
| Dividend | 0.62 |
| Forward Dividend | 0 |
| Dividend Yield | 3.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|